Summary
Pfizer announced that it had received FDA approval for DAURISMO to treat newly diagnosed elderly patients with acute myeloid leukemia.
The FDA approved DAURISMO along with chemotherapy based on the phase 2 study where the combination was shown to reduce the risk of death by 54%.
Pfizer received another FDA approval about 12 months ago for a drug named MYLOTARG to treat a different AML population.
DAURISMO is being explored in multiple phase 3 BRIGHT studies, exploring it in combination with other commonly used therapies to treat AML.
Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our model portfolio. Get started today »
Recently, Pfizer (PFE) announced that it had obtained FDA approval for a drug known as DAURISMO (glasdegib). The FDA approved this drug to treat newly diagnosed patients with Acute Myeloid Leukemia (AML) who are 75 years of age or older. I believe that this FDA approval provides great hope for these patients, because it will give them another more viable option for treatment. This approval is good for Pfizer's oncology pipeline, and that's why I believe it is a good buy.
